Michel Audran

Michel Audran

Auto-generated profile, based on publicly available information

Michel Audran

Département des analyses, Agence Française de Lutte contre le Dopage (AFLD), Châtenay-Malabry, France

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 March 2020 in Drug Testing and Analysis
Verified
Journal Article
Closed access
PDF file
LNLuca Narduzzi
Luca Narduzzi
GDGaud Dervilly
Gaud Dervilly
MAMichel Audran
Michel Audran
BBBruno Le Bizec
Bruno Le Bizec
CBCorinne Buisson
Corinne Buisson

4 April 2020 in Drug Testing and Analysis
Verified
Journal Article
Closed access
PDF file
LNLuca Narduzzi
Luca Narduzzi
GDGaud Dervilly
Gaud Dervilly
AMAlexandre Marchand
Alexandre Marchand
MAMichel Audran
Michel Audran
BBBruno Le Bizec
Bruno Le Bizec
CBCorinne Buisson
Corinne Buisson

26 May 2003 in International Journal of Sports Medicine
Verified
Journal Article
Closed access
PDF file
EVE. Varlet-Marie
E. Varlet-Marie
AGA. Gaudard
A. Gaudard
MAM. Audran
M. Audran
RGR. Gomeni
R. Gomeni
FBF. Bressolle
F. Bressolle
The aim of this study was to develop a pharmacokinetic model that takes into account the negative feedback loop of endogenous erythropoietin production observed after repeated recombinant human erythropoietin administration. A pharmacodynamic data analysis was performed using the changes in i) reticulocyte count, ii) serum levels of soluble transferrin receptors, and iii) soluble transferrin receptors/serum proteins ratio as an index of the therapeutic effect of the hormone. Nine athletes were included in the study; they received repeated subcutaneous administrations (50 IU × kg-1per day) of recombinant human erythropoietin. The mean half-life of the terminal part of the curve was 35.5 h, and the total clearance was 17 ml × h-1 × kg-1. The total clearance was about two times higher in athletes than in untrained subjects (5.5 - 7.5 ml × h-1 × kg-1) and the half-life period of plasma erythropoietin after subcutaneous administration was five times longer compared to intravenous administration (4 to 7 h). Thus, after subcutaneous administration, the terminal part of the curve should correspond to the absorption phase, instead of to the elimination phase (flip-flop phenomenon). The pharmacodynamic relationship based on a sigmoid E max model can be reasonably used to relate the changes observed in the markers to recombinant human erythropoietin administration. Recombinant human erythropoietin induces a delayed increase in reticulocytosis and in soluble transferrin receptor levels. In comparison with baseline, the increase of these markers became significant from the third and the tenth day after the initial administration of the hormone, respectively. These results were in accordance with the equilibration delay computed from the pharmacokinetic-pharmacodynamic data modelling (half-life of 25.7 h and 10 days, respectively). The recombinant hormone was well tolerated during this study.

1 January 1995 in Hormone Research
Verified
Journal Article
Closed access
RGRaynald Gareau
Raynald Gareau
GBGuy R. Brisson
Guy R. Brisson
CCClaire ChÉNard
Claire ChÉNard
MGMarie-Guylaine Gagnon
Marie-Guylaine Gagnon
MAMichel Audran
Michel Audran
Erythropoietin (Epo) represents for some athletes the ultimate tool to gain an edge over their peer competitors. Underground information indicates that its usage is spreading at an epidemic pace since no analytical technique is yet available to detect its utilization. We hereby report observations obtained from analysis of urine specimens collected from top-level athletes after international-calibre competitions. Possible Epo misuse was evaluated by the measurement of urine total degradation products (TDPs), excretory fragments attributed by Sakakibara et al. to the fibrinolytic action of Epo. Markedly elevated urine TDP levels were measured in more than 13% of the 76 top-level athletes evaluated in this study. Analyses of urine specimens from a control hockey player group and from out-of-competition resting subjects indicate that the urine TDP content is not significantly influenced by exercise per se. Solid confirmation of TDP measurement as a sound probe to detect illicit Epo users should come from controlled studies with concomitant administration of Epo.

1 December 2003 in Bulletin de l'Académie Nationale de Médecine
Verified
Journal Article
Closed access
MAMichel Audran
Michel Audran
Philippe ConnesPhilippe Connes
Philippe Connes
EVEmmanuelle Varlet-Marie
Emmanuelle Varlet-Marie